- Pages
- 2
- Published in
- United States of America
Zevra Therapeutics Receives Fda Acceptance of Resubmission of Nda for Arimoclomol as a Treatment for Niemann-Pick Disease Type C
2024
Accessing this content requires a membership
If your institution is a member, please log into Policy Commons from a link provided by your institution. This typically involves logging in via a menu managed by your library.
Add to list
Citation
NPD, 2024. Zevra Therapeutics Receives Fda Acceptance of Resubmission of Nda for Arimoclomol as a Treatment for Niemann-Pick Disease Type C, NPD: National Niemann-Pick Disease Foundation.
United States of America.
Retrieved from https://coilink.org/20.500.12592/1wgx8gf on 22 Oct 2024. COI: 20.500.12592/1wgx8gf.
Full-page Screenshot
